30 completed, 15 recruiting, 15 unknown, 6 terminated. 22 Phase 1, 21 Phase 2, 14 Not applicable, 3 Phase 3, 3 Phase 4.
Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Micro Assays for HemATology Malignancies Antibody Treatment blood sampling - Hematological Malignancy | Not applicable | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 166 | 2026-12-01 | 2026-10-29 |
| KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies MEN2312 - Hematological Malignancy | Phase 1 / Phase 2 | Not yet recruiting | Stemline Therapeutics, Inc. | 115 | 2026-10-30 | 2026-10-14 |
| Halt Aging in Survivors of Blood Cancers Behavioral Coaching Intervention, Virtual Exercise Platform - Hematological Malignancy, Leukemia | Not applicable | Recruiting | University of Nebraska | 180 | 2026-04-09 | 2026-07-01 |
| Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients SWA (standardized root extract of Withania somnifera) - Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease | Phase 1 / Phase 2 | Recruiting | Tata Memorial Centre | 54 | 2025-01-28 | 2026-07-24 |
| Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies CAR-T - Multiple Myeloma, B-cell Lymphoma | Phase 1 | Recruiting | The Third Affiliated Hospital of Southern Medical University | 60 | 2025-01-15 | 2025-01-06 |
| Investigation of the Effects of Prehabilitation Education Delivered Through a Mobile Compatible Website on Quality of Life and Symptoms in Patients Undergoing Hematopoietic Stem Cell Transplantation Prehabilitation education provided via mobile compatible website - Hematological Malignancy, Prehabilitation | Not applicable | Active not recruiting | Saglik Bilimleri Universitesi | 36 | 2024-12-13 | 2025-07-15 |
| Middle East Study of Infections in Patients With Hematological Malignancies No Intervention: Observational Cohort - Hematological Malignancy, Hematopoetic Stem Cell Transplantation | Recruiting | Hamad Medical Corporation | 1000 | 2024-09-15 | 2026-10-30 | |
| Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections, Recombinant Human Interleukin-2 Injections - Hematological Malignancy, Lymphocytopenia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 50 | 2024-09-01 | 2024-09-19 |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product No Intervention - Hematological Malignancy, Solid Tumor Malignancy | Recruiting | Century Therapeutics, Inc. | 375 | 2024-04-29 | 2025-06-25 | |
| Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells - Hematological Malignancy | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 64 | 2024-04-22 | 2026-08-20 |
| PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM Thymoglobulin Injectable Product - Hematological Malignancy | Phase 2 | Unknown | Institut Paoli-Calmettes | 27 | 2024-03-31 | 2024-02-20 |
| Is Ibrutinib-related Atrial Fibrillation Dose Dependent ibrutinib exposure - Hematological Malignancy, Atrial Fibrillation | Unknown | University Hospital, Caen | 18000 | 2024-03-01 | 2024-03-05 | |
| Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD Physical therapy - Graft-versus-host-disease, Graft Versus Host Disease, Chronic | Not applicable | Unknown | University of Seville | 108 | 2024-03-01 | 2024-02-28 |
| Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia Eravacycline - Hematological Malignancy, Neutropenia | Phase 2 | Recruiting | West Virginia University | 55 | 2024-02-19 | 2026-04-16 |
| A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy Locus Health iPhone App - Solid Tumor, Hematological Malignancy | Active not recruiting | Inova Health Care Services | 53 | 2023-10-26 | 2026-09-25 | |
| An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies YY201 - Advanced Solid Tumor, Hematological Malignancy | Phase 1 | Recruiting | Shanghai Yuyao Biotech Co., Ltd. | 96 | 2023-10-26 | 2024-01-31 |
| Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease. Standardized Withaferin A (SWA) - Hematological Malignancy, GVHD - Graft-Versus-Host Disease | Phase 2 | Recruiting | Tata Memorial Centre | 34 | 2023-09-23 | 2026-07-16 |
| A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) Nemtabrutinib - Hematological Malignancy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 40 | 2023-08-28 | 2024-09-19 |
| First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors OT-A201, IMids, Bevacizumab - Hematological Malignancy, Solid Tumor | Phase 1 | Recruiting | Onward Therapeutics | 150 | 2023-07-10 | 2025-03-20 |
| The Effect of Music Therapy on Comfort, Pain and Anxiety Musictherapy - Bone Marrow Disease, Hematological Malignancy | Not applicable | Completed | Izmir Bakircay University | 66 | 2023-04-01 | 2023-07-27 |
Showing 20 of 73. Sign in to see all of them.
Hematologic Neoplasms (73) · Leukemia (6) · Lymphoma (6) · Neoplasms (6) · Multiple Myeloma (5) · Graft vs Host Disease (4) · Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Invasive Fungal Infections (3) · Neutropenia (3) · Recurrence (3) · Bone Marrow Failure Disorders (2) · Bronchiolitis Obliterans Syndrome (2) · COVID-19 (2) · Febrile Neutropenia (2)
Hemic and Lymphatic Diseases (73) · Neoplasms by Site (73) · Hematologic Diseases (72) · Neoplasms (67) · Immune System Diseases (16) · Pathological Conditions, Signs and Symptoms (13) · Neoplasms by Histologic Type (11) · Immunoproliferative Disorders (10) · Lymphoproliferative Disorders (10) · Pathologic Processes (9) · Lymphatic Diseases (8) · Bone Marrow Diseases (6) · Cardiovascular Diseases (6) · Infections (6) · Blood Protein Disorders (5)
Cyclophosphamide (4) · fludarabine (3) · Blood Specimen Collection (2) · Bortezomib (2) · Immunotherapy, Adoptive (2) · fludarabine phosphate (2) · 68Ga-pentixafor (1) · ARQ531 (1) · Antibodies, Bispecific (1) · Bevacizumab (1) · Cilastatin, Imipenem Drug Combination (1) · Cytarabine (1) · Dexamethasone (1) · Etanercept (1) · Etoposide (1)
Institut Paoli-Calmettes (3) · Hangzhou Sumgen Biotech Co., Ltd. (2) · Tata Memorial Centre (2) · West Virginia University (2) · Zhongnan Hospital (2) · Aaron Cumpston, PharmD, BCOP (1) · Alla Keyzner (1) · Amsterdam UMC, location VUmc (1) · Antengene Therapeutics Limited (1) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1) · Astellas Pharma Global Development, Inc. (1) · Beckman Coulter, Inc. (1) · Centre Hospitalier Universitaire de Besancon (1) · Century Therapeutics, Inc. (1)
United States (25) · France (12) · China (11) · Israel (5) · Spain (5) · Canada (4) · Belgium (3) · Denmark (3) · Italy (3) · Turkey (Türkiye) (3) · Georgia (2) · India (2) · Netherlands (2) · Ukraine (2) · Argentina (1)
Aaron Cumpston, PharmD, BCOP (2) · A. Samer Al-Homsi, MD (1) · Aaron Cumpston, PharmD (1) · Alina Gerrie, MD, FRCPC (1) · Alla Keyzner, MD (1) · Anca Colita, MD (1) · Anupa Kudva, MD (1) · Donna Hogge (1) · Dr. Michael Har-Noy (1) · Dr.Akanksha Chichra, DNB (1)
PMID 19282026, PMID 23802653, PMID 26408225, PMID 30904387, PMID 32160294, PMID 32416453, PMID 5449164, PMID 10845900, PMID 11301861, PMID 12663454, PMID 16575919, PMID 18997826, PMID 21558065, PMID 22110505, PMID 22410750, PMID 22510384, PMID 22533831, PMID 22754076, PMID 22982675, PMID 23892326, PMID 25040144, PMID 25452693, PMID 26699701, PMID 26719433, PMID 26824940, PMID 26959007, PMID 27250656, PMID 27899357, PMID 28193214, PMID 28856437, PMID 29171820, PMID 30629902, PMID 31678539, PMID 32043777, PMID 32409691, PMID 32537114, PMID 32684166, PMID 32718876, PMID 33080623, PMID 33574236, PMID 34031051, PMID 34071607, PMID 34204308, PMID 34464155, PMID 34765323, PMID 34767652, PMID 3513012, PMID 35432352, PMID 35469070, PMID 35488407
2014 (1)